Back to Search
MAXWELL LEVIS, PHD, LICSW
PHD, LICSW
Social Worker
NPI: 1659851954Individual
Specialties, Licenses & Credentials
Social WorkerPrimary
Social Worker
Code: 104100000X
LICSW127369(MA)
Research & Publications (20)
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
PMID 19109557·Blood·2009
3-trial
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.
PMID 19029442·Blood·2009
3-trial
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
PMID 19654408·Blood·2009
7-preclinical
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
PMID 18955566·Blood·2009
7-preclinical
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
PMID 18483374·Clin Cancer Res·2008
3-trial
Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.
PMID 18452067·Leuk Lymphoma·2008
6-review
Images in clinical medicine. FLT3 Mutation and acute myelogenous leukemia with leukostasis.
PMID 17942876·N Engl J Med·2007
5-case
FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells.
PMID 17851558·Leukemia·2007
7-preclinical
Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells.
PMID 17686054·Br J Haematol·2007
8-other
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
PMID 17671131·Clin Cancer Res·2007
3-trial
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.
PMID 17562873·Blood·2007
3-trial
FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells.
PMID 17359372·Br J Haematol·2007
8-other
Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.
PMID 17047150·Blood·2007
8-other
Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
PMID 16869825·Br J Haematol·2006
8-other
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.
PMID 16857987·Blood·2006
8-other
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.
PMID 16857985·Blood·2006
3-trial
Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner.
PMID 16761017·Leukemia·2006
8-other
Internal tandem duplications of the FLT3 gene are present in leukemia stem cells.
PMID 15797998·Blood·2005
7-preclinical
FLT3 and acute myeloid leukemia: what is the wild type receptor up to?
PMID 16330422·Haematologica·2005
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3928 MAIN ST
MANCHESTER, VT 05254 - Phone
- (802) 768-1216
Quick Facts
- NPI
- 1659851954
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile